Target
$74.12 → $74.11
Current stock research snapshot · 7/31/26 26 days old
CRSPCRISPR Therapeutics
Investment conviction●●○○○2 of 5 · current snapshot
Research target$74.11Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed 7/31/26
Market cap$4.69BSnapshot value · 7/31/26
Research history
See all CRSP changes ↗What changed
Healthspan taxonomy seed — see taxonomy_path
CRISPR Therapeutics CTX001 (Casgevy) launch revenue; CTX310/320 cardiovascular gene editing data; Q2 2026 earnings
Thesis breaks if Aug 28 2026 ESC CTX310 readout shows ANGPTL3/LDL suppression decay (hepatocyte turnover), CASGEVY economics stay net-negative long-term, Broad/ToolGen IP adverse outcome, or CASGEVY revenue stalls QoQ. (vault 2026-08)
Bullish — Citizens maintains $80 PT Market Outperform on gene-therapy data Aug 25 2026; ARK model sees multi-billion upside [X search Aug 2026]
Snapshot · 7/31/26🟡 Mixed · ins-$3.3M · 13F 11+/8-×0.5 · short↓0.25
Snapshot · 7/31/26